Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

Amgen Neupogen

  • News

Executive Summary

PLA filing for the white blood cell growth factor was completed on Dec. 28. Amgen is seeking to market Neupogen (G-CSF, or granulocyte colony stimulating factor) as an adjunct to chemotherapy in certain cancers, primarily small cell lung cancer. The PLA includes data on more than 700 cancer patients from eight clinical centers in the U.S. and Europe.

You may also be interested in...



Sanofi Paid $14.6bn In Rebates In 2020; Net Prices Were Down

The company released an annual pricing report, showing that Sanofi's US average net prices declined for the fifth year in a row.

Can Vir/GSK’s COVID-19 Antibody Prove Its Worth In Early Disease?

Other antibody treatments have shown efficacy in early-stage disease after faltering in hospitalized patients.

Digital Health Roundup, January/February 2021: The Continued Rise Of AI, Telehealth

In this new roundup feature focusing on the most notable developments in digital health, we pick the key news from the year so far. 

Table

View full table

Tags:
UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By